The Technical Analyst
Allakos Inc [ALLK]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Allakos Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.89% $1.040
America/New_York / 19 apr 2024 @ 12:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 91.39 mill |
| EPS: | -2.14 |
| P/E: | -0.490 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 87.87 mill |
| Avg Daily Volume: | 0.827 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.490 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.08x |
| Company: PE -0.490 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.288 (-72.33%) $-0.752 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.925 - 1.155 ( +/- 11.06%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-06 | Radford Harlan Baird | Sell | 32 142 | Common Stock |
| 2024-03-05 | Tomasi Adam | Sell | 47 392 | Common Stock |
| 2024-03-04 | Alexander Robert | Sell | 70 910 | Common Stock |
| 2024-02-16 | Radford Harlan Baird | Buy | 900 000 | Stock Option (Right to buy) |
| 2024-02-16 | Lee Chin Hyok | Buy | 500 000 | Stock Option (Right to buy) |
| INSIDER POWER |
|---|
| 57.99 |
| Last 96 transactions |
| Buy: 11 461 350 | Sell: 2 630 713 |
Forecast:
14:14 - $1.045
Live Trading Signals (every 1 min)
Forecast
1: 12:44 - $1.040
Forecast 2: 13:34 - $1.039
Forecast 3: 14:14 - $1.045
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.040 (-1.89% ) |
| Volume | 0.153 mill |
| Avg. Vol. | 0.827 mill |
| % of Avg. Vol | 18.51 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALLK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $1.285 | N/A | Active |
|---|
ALLK
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Latest Press Releases
2024-03-14 16:02:00 - Press Release
Allakos Provides Business Update And Reports Fourth Quarter And Full Year 2023 Financial Results
San carlos, calif., march 14, 2024 (globe newswire) -- allakos inc. (the “company”) (nasdaq: allk), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended december 31, 2023.
2024-02-26 07:02:00 - Press Release
Allakos Presents Preclinical Data Highlighting Inhibition Of Mrgprx2-mediated Mast Cell Activation With Ak006 At Aaaai 2024
– atopic dermatitis and prurigo nodularis skin lesions show evidence of mrgprx2 mast cell activation and activated macrophages –
2024-02-12 23:45:00 - Press Release
Investor Action Alert: The Schall Law Firm Announces It Is Investigating Claims Against Allakos Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / february 12, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of allakos inc. ("allakos" or "the company") (nasdaq:allk) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-02-12 07:02:00 - Press Release
Allakos Announces Publication Highlighting Ak006 Mast Cell Inhibition
– data provide insights on the signaling pathways involved with ak006 mast cell inhibition –– ak006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells –
2024-02-07 18:25:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Allakos Inc. - Allk
New york , feb. 7, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of allakos, inc. ("allakos" or the "company") (nasdaq: allk). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
Latest News
2024-04-09 06:31:00 - InvestorPlace
3 Biotech Stocks to Dump Before They Go to Zero
It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason.
2024-04-04 09:41:13 - Zacks Investment Research
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions
Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2024-01-17 13:11:30 - Zacks Investment Research
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.
2024-01-16 11:36:49 - InvestorPlace
Why Is Allakos (ALLK) Stock Down 57% Today?
Allakos (NASDAQ: ALLK ) stock is taking a beating on Tuesday after the clinical stage biopharmaceutical company revealed results from its latest study. The bad news here comes from the company's Phase 2 and Phase 2b clinical trials of lirentelimab.
2024-01-16 11:26:24 - Zacks Investment Research
Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?
Here is how Allakos Inc. (ALLK) and McKesson (MCK) have performed compared to their sector so far this year.
2024-01-16 07:30:43 - Reuters
Allakos to stop further development of skin disease drug, plans job cuts
Allakos Inc said on Tuesday that it plans to discontinue the development of its experimental skin disease drug after it failed two mid-stage studies.
2023-09-27 12:10:16 - The Motley Fool
Why Shares of Allakos Are Up Wednesday
An analyst's recommendation may have helped boost Allakos stock. Allakos has two lead therapies to treat autoimmune skin disorders.
2023-09-18 02:07:15 - Seeking Alpha
Scratching The Surface: Allakos' Novel Take On Urticaria
Allakos displays fiscal discipline with YoY reductions in R&D and G&A, suggesting resource reallocation to pivotal assets like lirentelimab. Lirentelimab's Phase 2a data is promising, particularly for omalizumab-refractory patients, but late-phase results are keys to the drug's validation. Investment Recommendation: Speculative "Buy" advised for bold investors. Initiate starter positions, closely monitor upcoming Phase 2b data and cash burn rate.
2023-05-21 09:23:18 - Seeking Alpha
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%, EHTH +13.2%, FLNC +9%, ALLK +7.5%. The Active ETF portfolio continues with YTD gains at +10.6%.
2023-05-12 17:00:53 - The Motley Fool
Why Allakos Stock Skyrocketed Nearly 9% Higher Today
An analyst bumped his recommendation higher. This closely followed an encouraging quarterly earnings report/business update from the biotech.